{"markup":"\u003C?xml version=\u00221.0\u0022 encoding=\u0022UTF-8\u0022 ?\u003E\n    \u003Chtml version=\u0022HTML+RDFa+MathML 1.1\u0022\n    xmlns:content=\u0022http:\/\/purl.org\/rss\/1.0\/modules\/content\/\u0022\n    xmlns:dc=\u0022http:\/\/purl.org\/dc\/terms\/\u0022\n    xmlns:foaf=\u0022http:\/\/xmlns.com\/foaf\/0.1\/\u0022\n    xmlns:og=\u0022http:\/\/ogp.me\/ns#\u0022\n    xmlns:rdfs=\u0022http:\/\/www.w3.org\/2000\/01\/rdf-schema#\u0022\n    xmlns:sioc=\u0022http:\/\/rdfs.org\/sioc\/ns#\u0022\n    xmlns:sioct=\u0022http:\/\/rdfs.org\/sioc\/types#\u0022\n    xmlns:skos=\u0022http:\/\/www.w3.org\/2004\/02\/skos\/core#\u0022\n    xmlns:xsd=\u0022http:\/\/www.w3.org\/2001\/XMLSchema#\u0022\n    xmlns:mml=\u0022http:\/\/www.w3.org\/1998\/Math\/MathML\u0022\u003E\n  \u003Chead\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/js\/js_itu2PgFdrjV-docKmLK8Jn5oXe_05RgvQh73eOhI_mE.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_at_symbol.js?nzn6ve\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_article_reference_popup.js?nzn6ve\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/js\/js_I8yX6RYPZb7AtMcDUA3QKDZqVkvEn35ED11_1i7vVpc.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\n(function(i,s,o,g,r,a,m){i[\u0022GoogleAnalyticsObject\u0022]=r;i[r]=i[r]||function(){(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)})(window,document,\u0022script\u0022,\u0022\/\/www.google-analytics.com\/analytics.js\u0022,\u0022ga\u0022);ga(\u0022create\u0022, \u0022UA-15605596-27\u0022, {\u0022cookieDomain\u0022:\u0022auto\u0022});ga(\u0022set\u0022, \u0022page\u0022, location.pathname + location.search + location.hash);ga(\u0022send\u0022, \u0022pageview\u0022);ga(\u0027create\u0027, \u0027UA-189672-26\u0027, \u0027auto\u0027, {\u0027name\u0027: \u0027hwTracker\u0027});\r\nga(\u0027hwTracker.send\u0027, \u0027pageview\u0027);\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\njQuery.extend(Drupal.settings, {\u0022basePath\u0022:\u0022\\\/\u0022,\u0022pathPrefix\u0022:\u0022\u0022,\u0022highwire\u0022:{\u0022markup\u0022:[{\u0022requested\u0022:\u0022full-text\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022spmdc;12\\\/17\\\/10\u0022},{\u0022requested\u0022:\u0022long\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022spmdc;12\\\/17\\\/10\u0022}],\u0022ac\u0022:{\u0022spmdc;12\\\/17\\\/10\u0022:{\u0022access\u0022:{\u0022reprint\u0022:true,\u0022full\u0022:true},\u0022pisa_id\u0022:\u0022spmdc;12\\\/17\\\/10\u0022,\u0022atom_uri\u0022:\u0022\u0022,\u0022jcode\u0022:\u0022spmdc\u0022}}},\u0022googleanalytics\u0022:{\u0022trackOutbound\u0022:1,\u0022trackMailto\u0022:1,\u0022trackDownload\u0022:1,\u0022trackDownloadExtensions\u0022:\u00227z|aac|arc|arj|asf|asx|avi|bin|csv|doc(x|m)?|dot(x|m)?|exe|flv|gif|gz|gzip|hqx|jar|jpe?g|js|mp(2|3|4|e?g)|mov(ie)?|msi|msp|pdf|phps|png|ppt(x|m)?|pot(x|m)?|pps(x|m)?|ppam|sld(x|m)?|thmx|qtm?|ra(m|r)?|sea|sit|tar|tgz|torrent|txt|wav|wma|wmv|wpd|xls(x|m|b)?|xlt(x|m)|xlam|xml|z|zip\u0022,\u0022trackUrlFragments\u0022:1},\u0022ajaxPageState\u0022:{\u0022js\u0022:{\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/jquery.cluetip.js\u0022:1,\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/lib\\\/jquery.hoverIntent.js\u0022:1,\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/lib\\\/jquery.bgiframe.min.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_at_symbol.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_article_reference_popup.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/contrib\\\/google_analytics\\\/googleanalytics.js\u0022:1,\u00220\u0022:1}}});\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/cdn\/css\/http\/css_Xg7z6oCTVgud_Q0huYz9x9iiD5H_2YPSJ5z2ZViSWdY.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink rel=\u0027stylesheet\u0027 type=\u0027text\/css\u0027 href=\u0027\/sites\/all\/modules\/contrib\/panels\/plugins\/layouts\/onecol\/onecol.css\u0027 \/\u003E\u003C\/head\u003E\u003Cbody\u003E\u003Cdiv class=\u0022panels-ajax-tab-panel panels-ajax-tab-panel-sageoa-tab-art\u0022\u003E\u003Cdiv class=\u0022panel-display panel-1col clearfix\u0022 \u003E\n  \u003Cdiv class=\u0022panel-panel panel-col\u0022\u003E\n    \u003Cdiv\u003E\u003Cdiv class=\u0022panel-pane pane-highwire-markup\u0022 \u003E\n  \n      \n  \n  \u003Cdiv class=\u0022pane-content\u0022\u003E\n    \u003Cdiv class=\u0022highwire-markup\u0022\u003E\u003Cdiv xmlns=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022 id=\u0022content-block-markup\u0022 xmlns:xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cdiv class=\u0022article fulltext-view \u0022\u003E\u003Cspan class=\u0022highwire-journal-article-marker-start\u0022\u003E\u003C\/span\u003E\u003Cdiv class=\u0022section abstract\u0022 id=\u0022abstract-1\u0022\u003E\u003Ch2\u003ESummary\u003C\/h2\u003E\n            \u003Cp id=\u0022p-1\u0022\u003EFully bioresorbable scaffolds (BRS) offer a revolutionary treatment approach within the field of interventional cardiology. Since BRS devices provide temporary mechanical support to the vessel wall and then subsequently disappear, the technology has the potential to overcome many of the safety concerns associated with metallic drug-eluting stents, such as late stent thrombosis, prevention of late lumen vessel enlargement, and difficulties with surgical revascularization and imaging artifact with multislice computed tomography [Bourantas CV et al. \u003Cem\u003EInt J Cardiol\u003C\/em\u003E 2012; Serruys PW et al. \u003Cem\u003ELancet\u003C\/em\u003E 2009]. This article discusses the advances in BRS over the last 5 to 6 years.\u003C\/p\u003E\n         \u003C\/div\u003E\u003Cul class=\u0022kwd-group\u0022\u003E\u003Cli class=\u0022kwd\u0022\u003ELipid Disorders\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003EInterventional Techniques \u0026amp; Devices\u003C\/li\u003E\u003C\/ul\u003E\u003Cp id=\u0022p-2\u0022\u003EFully bioresorbable scaffolds (BRS) offer a revolutionary treatment approach within the field of interventional cardiology. Since BRS devices provide temporary mechanical support to the vessel wall and then subsequently disappear, the technology has the potential to overcome many of the safety concerns associated with metallic drug-eluting stents (DES), such as late stent thrombosis, prevention of late lumen vessel enlargement, and difficulties with surgical revascularization and imaging artifact with multislice computed tomography [Bourantas CV et al. \u003Cem\u003EInt J Cardiol\u003C\/em\u003E 2012; Serruys PW et al. \u003Cem\u003ELancet\u003C\/em\u003E 2009]. They may possibly deliver even more clinical benefits [Onuma Y et al. \u003Cem\u003ECirc J\u003C\/em\u003E 2011]. Patrick W. Serruys, MD, PhD, Erasmus University, Netherlands, discussed the advances in BRS over the last 5 to 6 years.\u003C\/p\u003E\u003Cp id=\u0022p-3\u0022\u003EBourantas et al. [\u003Cem\u003ECurr Cardiol Rep\u003C\/em\u003E 2012] noted that the potential advantages of this rapidly developing technology have led to a drive by industry to develop several types of BRS. Hence, numerous scaffolds are available today with different compositions (eg, metallic alloy or polymer), strengths, and weaknesses. Some of these are in development or undergoing preclinical evaluation, while others have already been implanted in humans. However, the interplay between mechanical dilation, resorption, and arterial response following implantation of bioresorbable scaffolds is still poorly understood [Strandberg E et al. \u003Cem\u003ECirc Cardiovasc Interv\u003C\/em\u003E 2012].\u003C\/p\u003E\u003Cp id=\u0022p-4\u0022\u003EOnuma et al. [\u003Cem\u003ECirc J 2011\u003C\/em\u003E] reported that the current generation of BRS is composed of either a polymer or a bioresorbable metal alloy. Numerous polymers are available, each with different chemical compositions, mechanical properties, and, consequently, bioabsorption times.\u003C\/p\u003E\u003Cp id=\u0022p-5\u0022\u003EThe most frequently used polymer in the current generation of BRS is poly-L-lactic acid (PLLA), which is already in widespread clinical use, with applications such as resorbable sutures, soft tissue implants, orthopedic implants, and dialysis media [Onuma Y, Serruys PW. \u003Cem\u003ECirculation\u003C\/em\u003E 2011].\u003C\/p\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-1\u0022\u003E\n         \u003Ch2 class=\u0022\u0022\u003EThe Bioresorption Process of Poly-L-Lactide\u003C\/h2\u003E\n         \u003Cp id=\u0022p-6\u0022\u003EIn the polylactic acid (PLA) family of polymers, molecular-weight degradation occurs \u003Cem\u003Ein vivo\u003C\/em\u003E mainly through hydrolysis, a bimolecular nucleophilic substitution reaction that can be catalyzed by the presence of either acids or bases [Onuma Y, Serruys PW. \u003Cem\u003ECirculation\u003C\/em\u003E 2011]. \u003Ca id=\u0022xref-fig-1-1\u0022 class=\u0022xref-fig\u0022 href=\u0022#F1\u0022\u003EFigure 1\u003C\/a\u003E shows the hydrolysis reaction in which water catalyzes a chain scission event at an ester bond.\u003C\/p\u003E\n         \u003Cdiv id=\u0022F1\u0022 class=\u0022fig pos-float  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/12\/17\/10\/F1.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Polyactide Degradation Mechanism\u0022 class=\u0022fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-1225688809\u0022 data-figure-caption=\u0022Polyactide Degradation Mechanism\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cimg class=\u0022fragment-image\u0022 alt=\u0022Figure 1.\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/12\/17\/10\/F1.medium.gif\u0022\/\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u00220 first\u0022\u003E\u003Ca href=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/12\/17\/10\/F1.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure 1.\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00221\u0022\u003E\u003Ca href=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/12\/17\/10\/F1.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00222 last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/14255\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption attrib\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure 1.\u003C\/span\u003E \n               \u003Cp id=\u0022p-7\u0022 class=\u0022first-child\u0022\u003EPolyactide Degradation Mechanism\u003C\/p\u003E\n            \u003Cq class=\u0022attrib\u0022 id=\u0022attrib-1\u0022\u003EReproduced from Onuma Y and Serruys PW. Bioresorbalbe Scaffold: The advent of a new era in Percutaneous coronary and peripheral revascularization. \u003Cem\u003ECirculation\u003C\/em\u003E 2011; 7(123): 779, with permission from the American Heard Association.\u003C\/q\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\n         \u003Cp id=\u0022p-8\u0022\u003EPLLA is a semicrystalline polymer. Ordered polymer chains constitute the crystalline component of the semicrystalline polymer, and random ones form the amorphous segment [Onuma Y, Serruys PW. \u003Cem\u003ECirculation\u003C\/em\u003E 2011]. The properties of semicrystalline polymers make them well-suited for mechanical support (eg, the scaffold). Amorphous polymers allow for a more uniform dispersion of the drug, and are therefore used in controlled drug release systems (eg, coating of the bioresorbable vascular scaffold system) [Onuma Y et al. \u003Cem\u003ECirc J\u003C\/em\u003E 2011].\u003C\/p\u003E\n         \u003Cp id=\u0022p-9\u0022\u003EFrom a chemical standpoint, resorbable implants undergo 5 stages that are not discrete and can overlap. Onuma and Serruys [\u003Cem\u003ECirculation\u003C\/em\u003E 2011] reported that the first stage is hydration of the polymer. After implantation of the polymeric resorbable device, the polymers begin to absorb water from the surrounding tissue. The second phase is depolymerization by hydrolysis. This is first observed by a reduction in molecular weight. The loss of mass (third stage) occurs when the implant no longer has cohesive strength and the polymer starts to fragment into segments of low-weight polymer. The fourth phase is assimilation or dissolution of the monomer. Lastly, the soluble monomer (eg, L-lactate) is changed into pyruvate, which eventually enters the Krebs cycle and is converted into carbon dioxide and water. These final products are excreted from the body through the kidneys or lungs, which results in complete bioresorption of the implant.\u003C\/p\u003E\n      \u003C\/div\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-2\u0022\u003E\n         \u003Ch2 class=\u0022\u0022\u003EKey Points\u003C\/h2\u003E\n         \u003Cp id=\u0022p-10\u0022\u003EBased on data from recent research, Prof. Serruys made several key points. One message was that PLLA fully disappears after 2 years. According to a study using optical coherence tomography (OCT) and histology in a porcine coronary artery model, struts that were still discernible by OCT at 2 years were compatible with largely bioresorbed struts. At 3 and 4 years, both OCT and histology confirmed complete integration of the struts into the arterial wall [Onuma Y et al. \u003Cem\u003ECirculation\u003C\/em\u003E 2010].\u003C\/p\u003E\n         \u003Cp id=\u0022p-11\u0022\u003EHe noted that bioresorption is a real phenomenon. In an assessment of the safety of the bioabsorbable everolimus-eluting stent, Prof. Serruys and colleagues found that 2 years after implantation, the stent was bioabsorbed, vasomotion was restored, and restenosis was prevented in the absence of a late safety signal, suggesting freedom from late thrombosis [Serruys PW et al. \u003Cem\u003ELancet\u003C\/em\u003E 2009].\u003C\/p\u003E\n         \u003Cp id=\u0022p-12\u0022\u003EOther data show that the impact of physiological cyclic strain and shear stress are essential for vessel wall biology. Hahn and Schwartz [\u003Cem\u003ENat Rev Mol Cell Biol\u003C\/em\u003E 2009] found that forces associated with blood flow are major determinants of vascular morphogenesis and physiology. Their review on mechanotransduction in vascular physiology and atherogenesis demonstrated that blood flow is crucial for blood vessel development during embryogenesis and for regulation of vessel diameter in adult life. It is also a key factor in atherosclerosis, which, despite the systemic nature of major risk factors, occurs mainly in regions of arteries that experience disturbances in fluid flow.\u003C\/p\u003E\n         \u003Cp id=\u0022p-13\u0022\u003EBrugaletta et al. [\u003Cem\u003EAtherosclerosis\u003C\/em\u003E 2012] quantified the circumferential healing process by OCT at 6 and 12 months following the implantation of the ABSORB bioresorbable vascular scaffold. A total of 58 patients (59 lesions) were included in the analysis. The neointima area was not different between 6 and 12 months follow-up (1.57\u00b10.42 vs 1.64\u00b10.77 mm\u003Csup\u003E2\u003C\/sup\u003E; p=0.691). There was also no difference in mean thickness of the neointima (median [interquartile range]) between the 2 follow-up time points (210 \u03bcm [180 to 260] vs 220 \u03bcm [150 to 260]; p=0.904). However, the symmetry of the neointima thickness was higher at 12 months follow-up than at 6 months (0.23 [0.13 to 0.28] vs 0.16 [0.08 to 0.21]; p=0.019).\u003C\/p\u003E\n         \u003Cp id=\u0022p-14\u0022\u003EAccording to Prof. Serruys, the implantation of bioabsorbable scaffolding not only seals and shields plaques, but it also caps them for up to 60 months of follow-up. Other benefits include wall thinning and plaque\/media reduction out to 5 years of follow-up with OCT showing late lumen enlargement (\u003Ca id=\u0022xref-fig-2-1\u0022 class=\u0022xref-fig\u0022 href=\u0022#F2\u0022\u003EFigure 2\u003C\/a\u003E).\u003C\/p\u003E\n         \u003Cdiv id=\u0022F2\u0022 class=\u0022fig pos-float  odd\u0022\u003E\u003Cdiv class=\u0022highwire-figure\u0022\u003E\u003Cdiv class=\u0022fig-inline-img-wrapper\u0022\u003E\u003Cdiv class=\u0022fig-inline-img\u0022\u003E\u003Ca href=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/12\/17\/10\/F2.large.jpg?width=800\u0026amp;height=600\u0026amp;carousel=1\u0022 title=\u0022Symmetry of Neointima at 6 and 12 months\u0022 class=\u0022fragment-images colorbox-load\u0022 rel=\u0022gallery-fragment-images-1225688809\u0022 data-figure-caption=\u0022Symmetry of Neointima at 6 and 12 months\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003E\u003Cimg class=\u0022fragment-image\u0022 alt=\u0022Figure 2.\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/12\/17\/10\/F2.medium.gif\u0022\/\u003E\u003C\/a\u003E\u003C\/div\u003E\u003C\/div\u003E\u003Cul class=\u0022highwire-figure-links inline\u0022\u003E\u003Cli class=\u00220 first\u0022\u003E\u003Ca href=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/12\/17\/10\/F2.large.jpg?download=true\u0022 class=\u0022highwire-figure-link highwire-figure-link-download\u0022 title=\u0022Download Figure 2.\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload figure\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00221\u0022\u003E\u003Ca href=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/content\/spmdc\/12\/17\/10\/F2.large.jpg\u0022 class=\u0022highwire-figure-link highwire-figure-link-newtab\u0022 target=\u0022_blank\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EOpen in new tab\u003C\/a\u003E\u003C\/li\u003E\u003Cli class=\u00222 last\u0022\u003E\u003Ca href=\u0022\/highwire\/powerpoint\/14257\u0022 class=\u0022highwire-figure-link highwire-figure-link-ppt\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EDownload powerpoint\u003C\/a\u003E\u003C\/li\u003E\u003C\/ul\u003E\u003C\/div\u003E\u003Cdiv class=\u0022fig-caption attrib\u0022\u003E\u003Cspan class=\u0022fig-label\u0022\u003EFigure 2.\u003C\/span\u003E \n               \u003Cp id=\u0022p-15\u0022 class=\u0022first-child\u0022\u003ESymmetry of Neointima at 6 and 12 months\u003C\/p\u003E\n            \u003Cq class=\u0022attrib\u0022 id=\u0022attrib-2\u0022\u003EReproduced from Brugaletta S et al. Circumferential evaluation of the neointima by optical coherence tomography after ABOSRB bioresorbable vascular Scaffold Implantation \u003Cem\u003EAtherosclerosis\u003C\/em\u003E 2012; 221(1):106\u2013112, with permission from Elsevier.\u003C\/q\u003E\u003Cdiv class=\u0022sb-div caption-clear\u0022\u003E\u003C\/div\u003E\u003C\/div\u003E\u003C\/div\u003E\n      \u003C\/div\u003E\u003Cul class=\u0022copyright-statement\u0022\u003E\u003Cli class=\u0022fn\u0022 id=\u0022copyright-statement-1\u0022\u003E\u00a9 2012 MD Conference Express\u00ae\u003C\/li\u003E\u003C\/ul\u003E\u003Cspan class=\u0022highwire-journal-article-marker-end\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Cspan id=\u0022related-urls\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Ca href=\u0022http:\/\/mdc.sagepub.com\/content\/12\/17\/10.abstract\u0022 class=\u0022hw-link hw-link-article-abstract\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView Summary\u003C\/a\u003E\u003C\/div\u003E  \u003C\/div\u003E\n\n  \n  \u003C\/div\u003E\n\u003C\/div\u003E\n  \u003C\/div\u003E\n\u003C\/div\u003E\n\u003C\/div\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_figures.js?nzn6ve\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_openurl.js?nzn6ve\u0022\u003E\u003C\/script\u003E\n\u003C\/body\u003E\u003C\/html\u003E"}